Two NIH researchers charged with smuggling 113 undeclared monkeypox vials onto Air France Detroit flight

Quick summary

Two NIH researchers — Vincent Munster and Claude Kwe, both working at a Biosafety Level 4 laboratory in Montana — were charged on June 2, 2026 with conspiracy to smuggle monkeypox into the United States and making false statements to federal law enforcement. The pair arrived at Detroit Metropolitan Airport on January 25, 2026 aboard an Air France flight from Paris, carrying 113 undeclared biological vials collected during fieldwork in Brazzaville, Republic of Congo, where an mpox outbreak was active. FBI testing of 20 vials found 17 contained deactivated mpox virus, one contained varicella, and two contained only human DNA.

No live mpox virus has been confirmed in the tested subset, and federal authorities have not issued public-health exposure notifications for passengers on the flight. When confronted by CBP officers, one researcher allegedly said: “I do this all the time.”

Federal prosecutors in the Eastern District of Michigan announced charges this week against two foreign nationals employed by the National Institutes of Health, alleging they boarded a commercial Air France itinerary in Brazzaville, transited Paris, and landed at Detroit Metropolitan Airport’s McNamara Terminal with 113 vials of viral material — none of it declared, none of it permitted under CDC import rules.

CBP officers flagged the pair after noticing a large black plastic case. The researchers told officers it held diagnostic and testing equipment. It held Styrofoam coolers packed with vials. That discrepancy — and the subsequent FBI lab analysis — is now the basis for federal criminal charges carrying a maximum of five years per count.

The vials traveled in the same pressurized baggage environment as every other passenger’s luggage on that flight. They were not detected by airline screening, not flagged at Charles de Gaulle, and not intercepted until CBP inspection at DTW. For everyone who flew that Paris–Detroit service on January 25, that sequence is the part that matters.

Munster is identified in court documents as chief of the Virus Ecology Section in the Laboratory of Virology at NIH’s Rocky Mountain Laboratories. Kwe is identified as a research fellow at the same facility. Both are charged with conspiracy to smuggle and making false statements — the latter charge stemming in part from Munster allegedly telling officers that any necessary documents were on his laptop while simultaneously denying he was carrying biological samples at all.

What CBP and the FBI found at DTW

The federal complaint, filed by the U.S. Attorney’s Office for the Eastern District of Michigan, lays out the inspection sequence in detail. CBP officers noticed the black plastic case during the standard arrival interview. When the researchers described it as diagnostic equipment, officers opened it. Inside: Styrofoam coolers. Inside those: 113 vials.

The FBI tested 20 of the 113. Results: 17 vials contained deactivated mpox virus, one contained varicella (chickenpox) virus, and two contained only human DNA. “Deactivated” means the pathogen has been chemically or thermally inactivated and is not capable of causing infection — but deactivation status does not eliminate the legal requirement to declare, permit, and properly package infectious biological materials for air transport. The researchers allegedly bypassed all three requirements.

The remaining 93 vials have not been publicly reported as tested — that gap is worth noting. Federal authorities have not issued a public-health advisory for passengers on the flight, and no exposure notifications have been sent, consistent with the deactivated-material finding so far.

This incident is not isolated from a broader pattern of heightened biosecurity enforcement at DTW. An Air France flight from Paris to Detroit was diverted to Montreal just weeks ago after CDC Ebola-related entry restrictions barred a passenger who had recently been in the Democratic Republic of Congo — a real-time illustration of how quickly biosecurity policy can reshape a commercial flight’s path.

How biosecurity law is supposed to work — and where it broke down

Under CDC regulations, importing infectious biological agents — including mpox, even in deactivated form — requires prior authorization through the CDC’s import permit program. DOT/PHMSA hazardous materials regulations, which incorporate ICAO Technical Instructions and IATA Dangerous Goods Regulations, separately require UN classification, triple-packaging, proper labeling, and a shipper’s declaration for infectious substances carried by air. These are not bureaucratic formalities — they exist because a packaging failure at altitude, or a mislabeled vial at a foreign transit hub, can create an exposure event with no clean containment option.

The alleged conduct here short-circuits every layer of that system. The researchers did not obtain CDC import permits. They did not file shipper declarations. They described the case to CBP officers as diagnostic equipment. And according to the federal complaint, one of them — when pressed — said the quiet part out loud: “I do this all the time.” That statement, if accurate, suggests this was not a one-time lapse but an established personal workaround inside a high-containment research environment.

Jurisdiction at DTW rests with CBP and CDC for border biosecurity. FAA oversees airworthiness and operational safety but does not independently verify biological cargo declarations — that responsibility sits with PHMSA and international standards bodies. Air France’s flight operations are not alleged to have violated any safety rules; the airline was not aware of the undeclared materials.

Steps for affected passengers and traveling researchers

CBP and FBI are the active enforcement bodies here, and the legal process is ongoing — but there are concrete actions depending on your situation.

• If you were on the January 25, 2026 Air France Paris–Detroit flight: Contact your primary care provider or local health department and reference the DOJ press release on the DTW mpox-smuggling case. Staff can cross-check current CDC mpox guidance and any local recommendations for post-travel monitoring. Federal authorities have not issued exposure notifications, but if you have health concerns, do not wait.
• If you are arriving at DTW on international flights in the coming weeks: Allow at least 60–90 minutes for immigration and customs. CBP questioning about research, medical, or biological materials is likely to be more detailed than usual. Review CBP’s guidance on bringing biological agents into the U.S. before you travel.
• If you are a researcher or healthcare professional transporting specimens on any carrier into a U.S. hub: Coordinate with your institution’s biosafety officer before departure. Obtain written CDC import permits where required, follow DOT/PHMSA triple-packaging and labeling rules, and carry printed documentation — not just files on a laptop — for CBP inspection on arrival.
• If you are traveling from the Republic of Congo or other active outbreak regions: Expect enhanced questioning at U.S. ports of entry regardless of whether you carry any materials. Processing times will be longer. Build that buffer into connections.

Watch: The U.S. Attorney’s Office for the Eastern District of Michigan is expected to announce preliminary hearing dates and potential indictment timelines in the coming weeks. If prosecutors pursue full charges, expect CBP and carriers to implement tighter preflight documentation checks for declared research cargo — particularly on routes from Central and West Africa through European hubs into the U.S.

Questions? Answers.